Clinical trials: Hepatic Tumors
Magnetic Resonance Imaging
The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma
This study is an exploratory study aiming to collect data on sensitivity and positive predictive value of IOP-enhanced (MPB-1523) MRI compared to dynamic multiphase MDCT for the detection of HCC.
- Trial name
- NCT03407495
- Testing
- IOP Injection (MPB-1523)
- Where
- 5 sites in Taiwan
- Volunteers
- 52 people
- Sponsor
- MegaPro Biomedical Co. Ltd.
Hepatocellular Carcinoma
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is administered continually once daily in…
- Trial name
- NCT00946153
- Testing
- Lenvatinib
- Where
- 12 sites in Japan, South Korea
- Volunteers
- 66 people
- Sponsor
- Eisai Co., Ltd.
Carcinoma, Hepatocellular
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer.
- Trial name
- NCT03347292
- Testing
- Regorafenib(Stivarga, BAY73-4506), Pembrolizumab
- Where
- 7 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or…
- Trial name
- NCT05862337
- Testing
- Anlotinib hydrochloride capsules, Penpulimab injection
- Where
- 67 sites in China
- Volunteers
- 480 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatic Impairment
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral dose of Elacestrant.
- Trial name
- NCT06126575
- Testing
- Elacestrant dihydrochloride
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Stemline Therapeutics, Inc.
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Hepatocellular
A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
In this study, CART cells are targeted to GPC3 by intratumor injected that we hope by this means could improve the local CAR-T cell numbers, meanwhile reduce the potential side effects.
- Trial name
- NCT03130712
- Testing
- GPC3-CART cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Hepatocellular Carcinoma
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
This is a study of pembrolizumab (MK-3475) in participants with previously systemically treated advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT02702401
- Testing
- Pembrolizumab, Best Supportive Care
- Volunteers
- 413 people
- Sponsor
- Merck Sharp & Dohme LLC
Embolization, Vascular Tumor
Evaluation of a Simple-Prep Controlled Embolic
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in…
- Conditions
- Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
- Trial name
- GPX (NCT06453642)
- Testing
- GPX® Embolic Device
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 114 people
- Sponsor
- Fluidx Medical Technology, Inc.
Solid Tumours
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab…
- Trial name
- IMFINZI-subQ (NCT07391670)
- Testing
- SC durvalumab + rHu, IV durvalumab, Tremelimumab
- Where
- 19 sites in Australia, Georgia and 3 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Liver Neoplasms, Hepatocellular Carcinoma
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)
This trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.
- Conditions
- Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- #HOPE4LIVER (NCT04573881)
- Testing
- HistoSonics System
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 24 people
- Sponsor
- HistoSonics, Inc.
Advanced Liver Cancer
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer.
- Trial name
- NCT03146637
- Testing
- Activated CIK, CIK
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to…
- Trial name
- NCT02415036
- Testing
- Delcath Hepatic Delivery System, Melphalan
- Where
- 3 sites in Germany
- Volunteers
- 17 people
- Sponsor
- Delcath Systems Inc.
Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples
- Conditions
- Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma
- Trial name
- NCT02762721
- Where
- 6 sites in United States, Italy
- Volunteers
- 131 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Hepatocellular Carcinoma
A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy
A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy
- Trial name
- NCT04161911
- Where
- United States
- Volunteers
- 1,426 people
- Sponsor
- Bristol-Myers Squibb
Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506
Moderate Hepatic Impairment Study Phase This phase employs a multicenter, open-label, parallel-group, single-dose study design.Two cohorts are established in this phase: Cohort A: Subjects with moderate hepatic impairment Cohort…
- Trial name
- HS-10506-114 (NCT07844967)
- Testing
- HS-10506
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Hepatocellular Carcinoma
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
To prove that the efficacy and safety of 'Green Cross CELL* Immuncell-LC group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(PEIT, RFA or operation) for hepatocellular carcinoma in…
- Trial name
- NCT00699816
- Testing
- Immuncell-LC
- Where
- 5 sites in South Korea
- Volunteers
- 230 people
- Sponsor
- GC Cell Corporation
Liver Cancer
A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer
This single-arm, open-label study assessed the efficacy and safety of Avastin (bevacizumab) treatment combined with transarterial chemoembolisation (TACE) in patients with localized unresectable liver cancer.
- Trial name
- NCT00576199
- Testing
- Bevacizumab, Transarterial chemoembolisation (TACE)
- Where
- 3 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche